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Abstract 
 
Representing more than 50% of a worldwide pharmaceutical market of US$ 400 billions, 
oral drug delivery systems become naturally the focus of many studies. For almost half a century 
scientists have attempted to develop a theoretical model capable of predicting oral drug 
absorption in humans. From steady state or quasi-equilibrium models to complex and 
computationally intractable dynamic modeling approaches, numerous research efforts tried to 
address the problem of interest. Surprisingly though, no simple insightful first-principle-based 
dynamic modeling approaches have been reported in the literature. It is the purpose of the present 
work to provide a simple dynamic distributed-parameter modeling approach for performance 
monitoring of oral drug delivery systems. 
As a consequence of the complexity of the gastrointestinal tract, drug oral bioavailability 
is influenced by many different parameters.  These parameters range from the compound’s 
physicochemical properties, the physiological factors of the environment to other factors inherent 
in the drug form itself known as encapsulation factors. Physicochemical properties account for 
parameters such as drug stability, solubility or diffusivity. Furthermore, the environment, namely 
the gastrointestinal tract, influences the drug delivery process to the body with its pH, intestinal 
transit time and the different transport mechanisms that take place. 
From a chemical engineering point of view, the human body’s anatomy can be analyzed 
and conceptually realized as a transport-reaction chemical system. Within the proposed modeling 
framework, the stomach is modeled as a non-ideal continuous-stirred tank reactor (CSTR) and the 
small intestine is the place where convection-diffusion occurs. The governing transport equations 
have been solved at steady state conditions in a small intestine represented by the lumen 
surrounded by its wall. The present work however develops a systematic dynamic first-principle-
based distributed-parameter modeling framework where the time-dependent convection-
diffusion-reaction model equations are analytically solved, offering the concentration profile in 
the small intestine lumen and in the wall from the moment the drug is administered until the 
complete absorption or disintegration of the drug particles. 
Once the modeling work is performed, a thorough and insightful sensitivity analysis can 
be conducted in order to assess the impact of the different process parameters on drug 
bioavailability. 
Keywords 
Bioavailability, drug delivery, mass balance approach, dynamic modeling, partial differential 
equations, sensitivity analysis, dynamic simulations. 
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I - Introduction 
 
 
Major scientific advancements in the medical and biomedical fields have resulted 
in an increased life expectancy and better public health during the last half of the 20th 
century. The pharmaceutical world-wide market was estimated to be US$ 200 billions in 
1990 and double this size: US$ 400 billions, by 2000. The driving force behind this 
progress is the considerable investment in research made by the pharmaceutical industry.  
Moreover, 80% of this market segment accounts for the US and the European top five 
consumers, headed by Germany and France. Notice, that these countries represent only 
15% of the world population. Therefore, this imbalance clearly indicates the great 
potential for new markets to be realized in emerging/developing countries, where the new 
generation of products of the pharmaceutical industry is expected to bring hope and 
social stability.  
 
Within this socioeconomic framework, it is not surprising that pharmaceutical 
companies are continuously striving for the development of new medically efficient 
products. In the US, around 18% of the turnover of this industry is invested in R&D 
efforts. In this fiercely competitive environment drug discovery is pursued on the fast 
track. Between the moment a new molecule and drug is found and designed, and the 
moment it will become available in the market seven to twelve years may elapse. The 
average cost of discovering and developing a new drug is more than US$ 530 millions. 
This price is justified: innovation is the key for pharmaceutical companies to remain 
competitive. 
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Since it can take years of research to discover and produce new molecular design-
based drugs, an alternative strategy toward the fulfillment of medical and therapeutic 
needs would advocate the reconsideration of the ways the drug is delivered. Indeed, 
instead of finding a new molecule to fit a given problem it can be worthwhile to try to 
induce a known molecule to act differently inside the body. Therefore, the development 
of a new drug should often be complemented by a new delivery process and protocol.  
 
The way the drug is delivered critically influences the way it works, not only on 
the medical but also on the marketing front. Notice that once the drug patent comes to its 
expiration, a slight modification of the delivery process provides the company with a new 
protected product. The psychological aspect of taking a drug is of importance as well. A 
patient might prefer having his prescription to be taken once a day, once a week or only 
in the morning. The convenience the patient finds in its drug prescription can be a key for 
the development and market introduction of a competitive product. The medical aspects 
primarily rely on factors such as drug bioavailability, and the widely accepted thesis that. 
the answer to different diseases may lie in the same molecule, distributed in diverse ways 
inside the body. 
 
It is therefore of primary importance to be able to design drug delivery systems in 
medically efficient and viable protocols, with fewer side effects and enhanced levels of 
psychological comfort for the patient. As noticed earlier, every new drug delivery system 
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implies new patents and the control of drug delivery processes is a strategic key 
comparative advantage in the pharmaceutical business.  
 
There are many ways to administer a drug:  oral, inhalation, implant or 
transdermal. Oral delivery is undoubtedly the most traditional one. It represents more 
than 50% of the drug market. The reason for this popularity is that this delivery process is 
recognized to be the most convenient way to absorb a drug. It is also the safest and 
cheapest. In comparison with other delivery processes, the success in having the patient 
accepting the medicine is higher for orally delivered drugs. 
 
When a drug is administered, it is of primary importance to know the quantity 
absorbed by the body as well as the absorption rate. To characterize the therapeutic 
effects of a drug, tests are realized at the different steps of its development. Every single 
parameter susceptible of having an influence on the drug efficiency or reliability is 
subject to study. For that reason, experimental and/or simulation studies should be 
conducted.  However, experiments, even if sometimes unavoidable, can incur dramatic 
costs in time and in money. The advantage to be in a possession of a process model is the 
ability to “recreate/re-enact” the experimental conditions, and thus replaces the cost of 
experiments by the cost of a computer, which is not a major investment these days. 
Capital expenses can be substantially curtailed in that manner. Also, where experiments 
can take days to run, including a human error factor that is growing with the amount of 
within the experiment needs to run, a computer can give a solution in minutes or seconds. 
An “if-then” approach of the problem can be performed, leading to a faster understanding 
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of the influence of the parameters under study. Furthermore, being able to generate 
results in a reproducible way, when experiments can include non controlled parameters 
influencing the final result and consequently non detectable errors, is precious for the 
reliability of the results obtained. Therefore, this approach presupposes that the model 
takes into account all key parameters that experiments include into their respective 
framework. The incredible advancements in digital computer technology  in the 1990’s, 
and at the same time the affordability of their prices opened doors to new discoveries and 
methodological perspectives. 
 
It is not surprising then that many research attempts have been made to develop 
models that provide an accurate characterization of the oral drug absorption process. 
These models are describing the intestinal tract functions under various conditions from 
steady state to dynamic. If steady state models provide a good understanding of the 
phenomenon taking place inside the gastrointestinal tract, they do not give access to 
absorption rates. Although they are usually more complicated, dynamic models present 
the benefit to offer concentration profiles and therefore absorption rates. Approaches that 
advocated the development of dynamic process models can be classified into three main 
categories:  mixing tank models, compartmental absorption and transit models, as well as 
dispersion models [1] . Out of the three existing categories of dynamic models, the 
dispersion models are based on fundamental physical and chemical laws (first principle-
based modeling approach),   and in that sense, they represent a more realistic approach. 
However, they suffer from mathematical complexity and computational intractability that 
can not be easily overlooked, complicating the implementation stage of the proposed 
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modeling methods and unnecessarily undermining their practicality from a process  
performance monitoring point of view. Therefore, there is a true need for the 
development of a new dynamic modeling framework for oral drug delivery systems that 
would allow the explicit incorporation of first-principles and fundamental transport-
reaction equation, while retaining theoretical simplicity, computational appeal, as well as 
the capacity to perform insightful investigations into the system’s dynamic behavior  and 
reliable process performance monitoring. It should be mentioned, that the proposed 
modeling framework should recognize the fact that, as a consequence of the complexity 
of the gastrointestinal tract, the drug oral bioavailability is influenced by many different 
parameters. These parameters range from the compounds’ physicochemical properties, 
the physiological factors of the environment to the factors inherent to the drug form itself 
known as encapsulation factors. Physicochemical properties account for parameters such 
as drug stability, solubility or diffusivity. The environment, namely the gastrointestinal 
tract, influences the drug delivery to the body with its pH, intestinal transit time and the 
different transport mechanisms taking place. 
 
Dispersion models are typically realized through fundamental transport equations 
describing the transport and reaction phenomena that occur in the intestine after the drug 
injection stage. These equations, which are typically parabolic partial differential 
equations, take into account the drug degradation kinetics, since the bioavailability of the 
drug relies on its stability [2] into the intestinal tract environment. The transport equations 
have already been solved at steady state conditions in a small intestine represented by the 
lumen surrounded by its wall [3]. The objective of this work is to set up and solve a 
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simple and analytical dynamic dispersion model for the concentration profile in the small 
intestine lumen and in the wall from the moment the drug is administered until the 
complete absorption or disintegration of the drug particles. The gastrointestinal tract is 
then represented by the succession of three compartments [4], representing the stomach, 
the small intestine, and the colon. The small intestine is typically composed of three 
segments: the duodenum, jejunum and ileum, but in the present study they are all lumped 
into a single element. Exchanges of substances happen between each of these organs and 
the surrounding fluids. However, drug absorption in the stomach and the colon are 
relatively slow, and it can be considered that the absorption happens only along the small 
intestine [5]. On the other hand, a stomach representation is necessary in order to get a 
boundary condition for the small intestine that is the focus of this study. The present work 
is thematically partitioned into three parts.  First, a model for the stomach chamber is 
developed based on a non-ideal continuous stirred tank reactor descriptive model. This 
non-ideal chemical reactor model allows the derivation of an expression for the drug 
concentration at the lumen entrance, which is going to serve as one of the requisite 
boundary condition in a well-posed distributed-parameter problem formulated on the 
basis of the basic transport-reaction equations that govern the drug behavior in the lumen. 
The concentration profile in the intestine lumen is then calculated using the method of 
characteristics that finally leads to an expression for the drug concentration into the small 
intestine wall, which is where the drug becomes available for absorption. From a 
mathematical point-of-view, the last steps, involve the analytical solution of a system of 
two coupled time-dependent partial differential equations representing the underlying 
basic transport-reaction equations.  Based on the proposed distributed-parameter dynamic 
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modeling framework a thorough and insightful sensitivity analysis is made, in order to 
assess the impact of key process parameters on drug bioavailability.  
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II - Literature review 
 
 
Grass et al [6] propose the definition for pharmacokinetics: “the study of the time 
course of drug and metabolite levels in different fluids, tissues and excreta of the body, 
and of the mathematical relationships required to describe them”. The purpose of this 
section is consequently to have an idea of what has been done in the study of drug 
absorption and what are the directions taken by authors. 
 
II.1- In vivo studies 
 
II.1.1 - Animal models: 
 
The use of an animal model is far to be straightforward and many studies are 
aimed at defining how to fit animal studies to humans. For instance, drug transport in the 
lymphatic system has been correlated to a number of animal models [7]. The model 
reliability is therefore linked to the animal chosen and depends on the physiological 
similarities between the animal and man. Rat is the species that has been the most 
studied, for example in the case of halofantrine by Porter and Charman [8, 9, 10]. The 
animal used can be either conscious or unconscious. The authors [9] detail a conscious rat 
model, and presents the advantages of using conscious rats. These advantages are mainly 
the inexpensive experiments, the robustness of rats and a success of 70% in describing 
the lymphatic transport. The model they set up was successfully reused in another study 
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aimed at the absorption into the blood of a lipophilic drug [11]. Rather than rats, studies 
can be conducted in animal which can be closer to humans from given points of view, 
like dogs, pigs or primates. Edwards et al [7] studied some larger animal models for the 
lymphatic drug transport as well, in an attempt to overcome the limitations they met in rat 
models. The pig, for instance, presents similarities to humans in its gastrointestinal tract. 
However the absolute mass of drug transported by the lymph cannot be calculated in 
pigs, since the lymph returns to the systemic circulation. The authors in [7] also 
developed sheep models, but the huge difference between ruminants and monogastric 
species like human limit the applications of this model. Their paper puts an emphasis on a 
dog model. The dog, an adult male greyhound, is conscious and anesthetized, and a 
cannula is inserted into a jejunal vein to the level of the portal vein and ligatured. All 
branches going to the thoracic duct are ligatured to assure the return of lymph to the main 
canal. The model is recognized to be successful in many points. It allows indeed the rapid 
detection of lipophilic drug candidates; it also permits to administer full size human doses 
and has been used to establish the role of lymphatic transport in oral bioavailability.  
An animal model can be influenced by many parameters. For instance [12] 
showed that fasting before or after the surgery influences the intestinal lymphatic drug 
transport. The lymph flow can increase by 75% depending on the solution that is going 
through the cannula [13]. In [7] is recognized the difficulty to assess the influence of 
anesthesia on the model. Their results are in conclusion tempered by the fact that a large 
amount of factors have an impact on the accuracy of the model estimations and that the 
experimental variables need to be controlled with attention. 
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II.1.2 - Future developments: 
 
These restraints lead to Danis and Wilding work [14]. It is recognized that getting 
some information on regional absorption in the jejunum, ileum or in the colon, using 
animal models is essential in the early steps of a drug development, since it is very hard 
to abandon a drug candidate once in the full development process. However the 
bioavailability in animals does not extent well to humans. The same statement is 
addressed by Grass and Sinko [6]. According to them, the most likely reason for the lack 
of correlation is differences in physiology, manifested as differences in absorption, 
metabolism, plasma protein binding, etc. They plotted the absolute bioavailability of 
various drugs reported in different animals frequently used for animal modeling versus 
the absolute bioavailability reported in humans. This plot is shown on figure 1 and gives 
a good picture of the difficulty to relate animal modeling to humans. In their review, [14] 
explain that some experimental bioavailability studies nowadays can be conducted in 
man, since some technological advances allowed the development of capsules able to 
release drugs in desired parts of the intestine. These “intelligent” capsules are then able to 
deliver a small quantity of drug, a sub-therapeutic dose, to evaluate a regional absorption 
in the gastro-intestinal tract. The absorption profile of a drug can then be establish in the 
whole GI tract, saving time in the early developments of the product. 
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Figure 1 Comparison between the absolute bioavailability in animals and the 
absolute bioavailability in humans. There is no apparent link between bioavailability in 
animals and bioavailability in humans. This illustrates the difficulty to rely on animals to 
assess the bioavailability of a drug in humans. 
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II.2 - Description of the system under study 
 
II.2.1 - The gastrointestinal tract [15] 
 
In her book, Human Anatomy and Physiology, Elaine Marieb divides the 
digestion process in six common steps. Three of them are used in drug absorption studies: 
• Mechanical digestion in the stomach, that breaks ingested particles in even 
smaller particles. 
• Chemical digestion, representing the chemical degradation of the particles or 
molecules. This phenomenon mainly happens in the stomach. 
• Absorption that is the course through the intestine wall of the digestion products 
from the lumen intestine to the blood.  
 
II.2.2 - The stomach 
 
Once the elements arrive in the stomach, this one contracts in order to break and 
mix them. The mixing movements are due to peristaltic waves. When these waves arrive 
at the basis of the stomach, they open the passage from the stomach to the small intestine. 
This allows the gastric evacuation in the intestine be a non-continuous process [15]. This 
process occurs as a series of jets with a period of twenty seconds [16]. Firmer and Cutler 
[18] considered the case of this non-continuous process for stomach emptying, by setting 
up a computer-based model. As the time dependence in their model was discretized, they 
explain that obtaining an analytical solution to their model would have been much more 
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difficult, but the emphasis they put on the process discontinuity enabled them to obtain 
good results in agreement with experiments ran on rats. 
However, stomach models in the literature commonly represent the stomach 
emptying as a continuous process, which is reasonable when comparing the length of the 
twenty seconds periods with the digestion time that is of the order of hours. Different 
mathematical functions have then been used to explain the stomach emptying. Hunt and 
Stubbs [17], with many others, used a decreasing exponential to describe the 
phenomenon. Numerous non-exponential functions are reported in [18], such as square 
root law and other various shapes. However, the decreasing exponential remains the most 
commonly used function. This leads to the following point in the development of drug 
absorption models: very often these models are built up in collaboration with chemical 
engineers, and the stomach is then assimilated to a chemical reactor [19,20] or to a 
compartment which is subject to physical and mathematical laws. The compartmental 
approach will be detailed further. For now, the chemical reactor aspect is very interesting 
because the exponential decrease is typical of the ideal single continuously stirred tank 
reactor (CSTR) output [21,22]. The fact that both of the decreasing exponential 
mathematical description and the CSTR modeling support each other explains why both 
have been using in a more straightforward way rather than slightly different approaches. 
 
II.2.3 - The small intestine 
 
In the small intestine all the absorption processes occurs. Marieb [15] gives a 
review of the small intestine anatomy. Its length is between 6 and 7 meters in a dead 
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human body, but only 2 meters in the alive human, because of the muscular tonus. It is 
composed of three segments, duodenum, jejunum and ileum, of relative lengths of 0.25 
meters, 2.5 meters and 3.6 meters. The microscopic anatomy of the small intestine is the 
key for the absorption. Roughly, the intestine can be described as a lumen surrounded by 
the intestine wall. The interface between the lumen and the wall is crucial for the 
absorption. The wall surface is composed of microvillus which increase the interface 
area, as shown on figure 2, extracted from [23]. The intestinal epithelium is a layer of 
cells attached between them with tight junctions. Their apexes form the apical surface 
that faces the intestine lumen. 
 
Figure 2 Schematic representation of intestinal epithelial cells. 
 
Due to the complexity of the interface between the lumen and the wall, many 
researchers have been working at the study of the phenomena occurring in this area in 
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order to characterize their relative influence on the absorption of the molecules from the 
intestine lumen to the intestine wall.  
The mucus is an aqueous mixture covering many epithelial surfaces in the human 
body. Its presence in the intestine affects the drug absorption. Khanvilkar et al. [24] 
studied the permeability of mucous gels. As they explain, the mucus is produced by the 
epithelial surface in the eyes, the respiratory tract but also the gastrointestinal tract, where 
it can have a thickness comprised between 50 and 450 µm [25,26]. In Khanvilkar [24] 
explicates the function of cytoprotection, lubrication, diffusion barrier. It is then as well a 
barrier to drug absorption. Moreover it promotes the formation of an unstirred water layer 
(UWL) [27] where the drug must diffuse before being absorbed across the epithelium. In 
their work for instance, Porter and Charman [28] put in plain words that the UWL is a 
major barrier to absorption of poorly water-soluble products. Some drug delivery systems 
can take advantage of it; these are the so-called muco-adhesive dosage forms [29], but 
except these latter, for drug absorption in the small intestine the following issues are 
addressed in [24]: 
• How the diffusion is affected by the mucus? 
• What factors are responsible for the drug diffusion transport through the mucus? 
They used several methods to study the diffusion phenomenon through the mucus. The 
first one, a classical diffusion cell, is composed of two stirred cells separated by a 
membrane holder. One of the compartments, the donor, is filled with a drug solution, and 
the other one, the receiver with a buffer. Mucus is sandwiched between two drug-
permeable membranes. Samples are then regularly taken in the two compartments, in 
order to determine the drug diffusion coefficient in the mucus. A second method 
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proposed is to use a known volume of mucus with one face exposed to the solution and 
after a certain time to measure the drug concentration in the mucus at different distances 
from the source. Some more sophisticated methods derived from UV spectrophotometric 
techniques [30] can be used. Their review also included a model for the drug diffusion 
coefficient in the mucus. This model, initially proposed by Peppas et al. [31], model the 
diffusion through the mucus, represented as a network, as a free-volume system, 
dependent on glycoprotein concentration, molecular size and density of cross links: 

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; where nD is the diffusion coefficient in the mucus, 
WD the one in water, mc the glycoprotein concentration, v  the specific volume of 
glycoprotein, jM  the average molecular weight, ir the radius in the network, k and 
k ′ are constants. Their conclusions were firstly a good prediction of the models 
developed, and secondly, and of main importance in our framework, the fact that while 
mucus appears to represent a significant barrier to the absorption of some compounds, in 
many cases it adds very little additional resistance to the adsorption process. Small 
molecules particularly diffuse without any restraint in the mucous gel. 
 
The specific case of highly lipophilic drugs is treated in [28]. This work exposes 
the challenges for this kind of drugs. The lipid digestion occurs in mainly three steps 
[32]: 
• Dispersion of the fat globules into an emulsion 
• Hydrolysis of the fatty acids at the oil/water interface 
• Dispersion of the digestion products into an absorbable form 
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This emulsion then goes into the duodenum. Once in the small intestine a barrier between 
the bulk and the membrane formed of an UWL is met by the drug molecules. The 
aqueous nature of this barrier is the reason why highly lipophilic drugs are a specific 
challenge. However, once in the membrane their lipophilicity is an advantage as it will be 
exposed further when dealing with the transport processes into the wall.  
 
After a description of the intestinal brush border, [23] studied the role of 
absorption enhancers in oral drug delivery. The effective delivery of a therapeutic agent 
via the oral route requires solubility, stability in stomach and the lumen and, as we just 
reviewed, the ability to pass through the intestine wall. This last parameter depends on 
the physical and chemical characteristics of the molecules. For instance, if intestinal 
permeability is good for simple dipeptides, which are actively transported, or small 
peptides, it becomes problematic for polar drugs and larger peptides and proteins. For 
these molecules the use of enhancers is suitable. These enhancers are reviewed in [23] 
with their description and action. Many of them exist, mainly bile salts and surfactants.  
Their role is to improve the aqueous solubility and the partition coefficient of the drug, 
when associated to it. Their action sometimes requires an alteration of the tight junctions 
or of the apical membrane of the intestinal epithelial cell (see figure above). The majority 
of them act directly on the apical membrane. 
 
The obstacles or helps molecules can meet when penetrating the intestine wall 
have been reviewed above. Let’s now introduce the important notion of partition 
coefficient. This number is the ratio between the concentrations of a substance in an 
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aqueous phase and in an oil phase. It gives an idea of the lipophilicity of the molecule it 
is related to. It is therefore linked to the absorption kinetics from the intestine lumen and 
the intestine wall, which are respectively of aqueous and lipidic nature. An example of 
the use of this coefficient in modeling drug absorption in the small intestine can be found 
in Idkaidek and Abdel-Jabbar work [33]. The concentration at the lumen-wall interface 
on the wall side is equal to the concentration on the lumen side times the drug partition 
coefficient. The partition coefficient is then used to obtain a boundary value for diffusion 
in the wall. 
The partition coefficient of a drug can be determined like described in [34]: two 
solutions of the same volume of oil on the one hand and of buffer on the other hand are 
mixed with a given amount of drug. When the equilibrium is reached the concentration of 
drug in both phases is measured, by UV spectroscopy for instance, and the ratio of the 
two concentrations gives the partition coefficient. 
 
Transport phenomena in the wall have been widely studied. The work proposed by 
Arturson et al. in [35] gives an excellent review of how a drug can be transported through 
the intestine wall. Four routes exist that a drug molecule can use in the intestine wall. 
These are exposed on the figure 3 below, extracted from [35]. The four routes are the 
following: 
• The passive transcellular route (1 on the figure) 
• The passive paracellular route (2 on the figure) 
• The carrier mediated route (3 on the figure) 
• The transcytosis route (4 on the figure) 
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Figure 3 The different transport routes for a molecule 
The transcytosis route is reserved for very specific molecules and is not considered as a 
very attractive transport route. As the carrier is saturable, as the drug concentration 
increase the contribution of the carrier mediated route will decrease relatively to the 
passive routes. So that, at a certain dose level of drug, the transport through the wall cells 
is due to passive transport. Therefore, passive transports are commonly accepted by 
authors as the main transport routes [23,35,36]. Between the two passive transports it 
would seem logical that a hydrophilic drug would use the paracellular route rather than 
the transcellular route, because of the lipidic nature of the cells. However, as [35] shows, 
the surface area of the luminal cell being 1000-fold larger than that of the paracellular 
space [37] and therefore the larger surface area of the cell membrane will compensate for 
the difference in the repartition between the cell membrane and the paracellular route. 
Passive drug absorption is often studied using Caco-2 (Colon Carcinoma Cell 
Line) cell monolayers, which are an excellent model for the passive pathways as it is 
shown in [38,39]. They are aimed at identifying how a drug is transported through the 
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intestinal epithelium and at identifying the most appropriate enhancer if there is a need 
for it.  
 
Figure 4 Comparison of partition coefficients when using a Caco2 cell line. 
Extracted from [35] 
 
 
II.3 - Dynamic models 
 
Now that all the essential concepts of the drug absorption are set up, a review of 
the dynamic models for oral drug absorption will be presented, based on the notions 
explained above. Dynamic models present the advantage upon steady state models to 
provide not only an estimation of the fraction of dose absorbed but also the absorbed drug 
concentration profiles with time. 
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As Grass and Sinko clarify in [6], in order to achieve an efficient research and 
development process for a new drug, there is a real need for competent models. These 
models must be based on pharmacokinetic properties. They divide them in single-
parameter, multi-parameter and combined models. 
Single-parameters models are often based on either the partition coefficient or the 
measurements in Caco-2 cells explained above. The problems met by these models are 
linked to the data used to run them. Larger sets of data are needed for better predictions. 
Consequently, a database for absorption parameters has been developed: the iDEA™ 
database, which has been explained and compared to another used database, Gastroplus™ 
in [40]. [6] concludes about single-parameter models with their efficiency in identifying 
significant parameters for drug absorption and their easiness of use, but this has to be 
balanced with their failure in meeting the test of broader datasets that limits their utility. 
Multi-parameters models behave in a closer way to reality, since they include 
mathematical descriptions of all the significant processes that influence the molecule 
interactions with its environment. Consequently they are more difficult to develop but 
also more predictive.  
 
Using a slightly different classification, Yu et al. reviewed in [41] the kind of 
dynamic models in three categories: 
• Dispersion models 
• Mixing tanks models 
• Compartmental absorption and transit models (CAT models) 
A dynamic distributed-parameter modeling approach for performance monitoring of oral drug delivery systems 25   
 
Pascal Eyriès  Worcester Polytechnic Institute Spring 2003 
Mixing tanks models, simpler than dispersion models on a mathematical point of 
view came out in the 1980’s. The principle of mixing tanks is to consider the 
gastrointestinal tract as a series of perfectly mixed tanks, with linear transfer kinetics. A 
model based on a single tank would allow a quantity of the drug to reach the colon as 
soon as it enters the small intestine, leading to an underestimation of the fraction 
absorbed. Several tanks would oblige the drug to spend some time in the intestine before 
reaching the colon, but each part of the small intestine would have the same problem, 
since the mixing tank representing each part would allow some of the drug entering to 
reach immediately the end of the segment. Based on this statement, the compartmental 
transit model was developed and replaces now mixing tanks models.  
The compartmental absorption and transit (CAT) model was developed by Yu in 
[41]. In each compartment a set of differential equations describes the drug movement 
and the drug absorption. Initially, this work is based on a previously published model for 
the transit only in the small intestine [42]. Then, the CAT model was ameliorated in [41], 
including drug absorption.    The transport problem through the small intestine is divided 
in several segments. Each segment can have a different volume and flow rate, but they all 
have the same transit rate constant. The transit rate constant is determined as a ratio 
between the number of compartments and the total transit time in the intestine. It is then 
considered that the drug spend a time equal to the transit time constant in each 
compartment. The absorption is assumed to be minor in the stomach and in the colon, but 
the drug is directly absorbed from one compartment of the small intestine to the plasma. 
The CAT approach is illustrated with 7 compartments on figure 5 below. 
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Figure 5 A schematic diagram of a compartmental absorption and transit (CAT) 
model. The model considers transit, degradation and absorption of the 
drug in the small intestine. 
 
The CAT model has since been improved by its authors in [43] in a saturable 
absorption model, to take into account both the passive and saturable absorption 
mechanisms. Many other authors worked on improving CAT models, leading to more 
and more efficient, but more and more intractable and computationally demanding 
models. Agoram et al. presented in [44] an Advanced CAT model able to simulate non 
linear response in drug bioavailability and taking into account the influence of inhibitors 
and inducers of enzymes. A schematic of this Advanced CAT model is given in figure 6. 
The compartment physiological parameters become compartment dependant, and the 
colon is included in the model.  
Mass balance approaches present the advantage to be based on the physics and 
chemistry laws describing the phenomenon occurring in the GI tract. These models 
remain quite simple as long as they are steady state models. Under dynamic conditions, 
mass balances in the small intestine have already been solved. Firmer [45] published a 
computer model based on a discretized mass balance to take into account the 
discontinuity of the stomach emptying. Almost a decade before Ni [46] had developed a 
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physical model for the 
 
Figure 6 ACAT model schematic. This model is more complicated than the 
previously shown CAT model and requires more computational 
effort.  
 
longitudinal fluid spreading in the small intestine, associated with the drug absorption. 
The model is based on a mass balance in a cylindrical geometry representing the small 
intestine. This mass balance was solved analytically for several input concentration 
profiles at the beginning of the intestine. They obtained an analytical solution using the 
Laplace transformation method, and provided a rigorous mathematical solution to their 
model with the use of the error function.  Radial diffusion of the drug molecules in the 
wall was not included in their model. Their model was applied to the rat small intestine 
case for different partition coefficients. The concentration profiles they obtained at the 
small intestine outlet are shown on figure 7. 
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Figure 7 Concentration profile at the small intestine outlet in a rat, calculated from 
Ni model. 
 
 
 
 
II.4 - Conclusion 
 
To conclude this literature review it can be said that there is a need for efficient, reliable 
models for oral drug absorption. Many approaches exist, but there is a lack of a simple, 
first principle based model. It is surprising to see that at this time no mass balance has 
been solved in a dynamic and simple way, taking into account both transport mechanisms 
through the intestine lumen and through the intestine wall. It is the purpose of this work 
to provide the solution to such a problem. 
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III - Modeling approach 
 
 
The stomach is modeled as a Continuously Stirred Tank Reactor [47] (CSTR). 
This approach has already been used to model different parts of the gastro-intestinal tract 
and present the advantage to be very flexible as shown hereafter. Indeed, chemical 
engineers are dividing chemical reactors in three main categories: batch reactors, plug 
flow reactors and CSTRs. Batch reactors are a closed process where chemical reactions 
take place in a closed environment. In plug flow reactors reactions take place along a 
stream and mixing between species occurs with the turbulence of the flow. In CSTRs the 
continuous species streams are mixed with a mechanical help (see figure above). In an 
ideal CSTR the concentration is assumed homogeneous all over the reactor and the 
residence time attains a mean reference value. However, in a real reactor the fluid 
particles spend a different time inside the reactor depending on the hydrodynamic profile 
of the reactor. Therefore, a distribution of the residence times characterizes the reactor. 
The residence time of a particle depends on the flow path this particle takes between the 
inlet and the outlet of the CSTR. The two ideal models of continuous reactors are the 
ideal models of CSTR on one hand and of plug flow reactor (PFR) on the other hand. A 
non ideal reactor can be assumed to behave in a way in-between these two types of 
perfect reactors. When the dominant behavior of the real reactor is plug-flow, the 
deviation of the reactor from ideality is represented by an axial dispersion model [21]. A 
way to describe the non ideal continuously stirred tank reactor is to replace it by an 
association of ideal CSTRs in cascade [21]. As the number of reactors in the cascade 
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increases, the modeled behavior gets closer to a PFR behavior. In this work, as the 
stomach is assumed to be a CSTR, the non ideality is modeled by the association of only 
two ideal CSTR in cascade. This choice allows us to observe a behavior closer from the 
CSTR behavior than from a PFR one. 
 
Figure 8 Stomach modeling, single CSTR and CSTRs in cascade 
The feeding strategy is assumed to be an impulse. It is considered that at a time 
0=t  a given number of drug molecules are deposited into the stomach, as the patient 
swallows his dose. Moreover, drug decomposition inside the stomach is taken into 
account. The drug decomposition kinetics is taken as a first order reaction, with a reaction 
rate k. Under these conditions the response on the concentration profile at the outlet of 
the stomach is given by the following expression: 
( ) ( )tkttctc ×−×

 ×−×

= exp2exp2
2
0 τττ     (1) 
 
Besides the stomach chamber, the small intestine is the main focus of our study. 
In the work presented in [2], Idkaidek considers the mass transfer into the small intestine 
by convection in the lumen and by diffusion into the walls. The small intestine is 
represented by a cylindrical geometry surrounded with a wall of constant width. This 
representation regroups duodenum, jejunum and ileum assembled in one single system. 
Stream In 
Stream 0ut
Stream 0 Stream 1 Stream 2 
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Note that drug decomposition kinetics is assumed to be first order, which is consistent 
with the assumption of diluted solution in the stomach. 
The assumption of a diluted solution in the intestine is in agreement with the 
continuous water secretion [2] and the kinetics is still first order. The transport processes 
occur at a constant temperature, the fluid velocity in the lumen is considered to be 
constant and the diffusion coefficient is held constant as well. 
In the lumen intestine the drug is transported by a convection phenomenon. The 
fluid going through the lumen is carrying the drug in the direction of drug decreasing 
concentration. Moreover the drug keeps on being degraded in the lumen obeying the 
same first order kinetics, but with a kinetics rate that can be different according to the 
different physiological conditions in the lumen in comparison with the stomach. 
A standard mass balance equation for the diluted drug in the lumen intestine yields: 
( ) ( ) ( )txcb
x
txca
t
txc
L
LL ,,, ×+∂
∂×=∂
∂       (2) 
where  
a  =  fluid velocity 
b  =  kinetic rate constant 
Lc = drug concentration in the lumen 
From the concentration calculated in the lumen intestine a boundary condition can 
be assessed for the wall using the drug partition coefficient P. This coefficient is a 
measure of how much the drug is lipophilic. As the lumen is mostly an aqueous phase, 
the cells of the intestine wall are lipoidal in nature, and therefore the drug partition 
coefficient quantifies the ability of the drug to go from the lumen to the wall across the 
wall membranes. This is a thermodynamic equilibrium. Two very important aspects of 
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our modeling approach lie in this drug partition coefficient concept. Firstly, the 
thermodynamic equilibrium is assumed to be reached at each moment. The time scales 
dealt with in the study of the fluxes inside the lumen intestine are supposed to be large 
enough for a thermodynamic equilibrium to be attained. Secondly, it would not be a 
reasonable assumption to consider only an axial flux in the lumen if the drug under 
consideration is of highly lipophilic nature. In that case the attraction of the molecule for 
the lipoidal phase might play a role in the mass balance considered to solve the drug 
concentration profile in the intestine lumen. When the phenomenon is under study at 
steady-state, as in [2], it makes sense to study drugs with partition coefficients greater 
than 1, since equilibrium is supposed to be reached in the mass balance treatment. 
However, with dynamic conditions if the phenomenon of attraction of the drug molecules 
by the wall cells is too important, the flux along the lumen intestine cannot be assumed to 
be only axial anymore. Our model has then to be restrained to drugs with a partition 
coefficient not higher than one, namely non-lipophilic drugs. 
Once in the small intestine wall, no fluid flux occurs and the drug transport is due 
to the only drug concentration gradient. Fick’s second law of diffusion describes this 
transport mode. The diffusion associated with the degradation kinetics yields to the 
following mass balance: 
( ) ( ) ( )tycb
y
tycD
t
tyc
W
WW ,
,,
2
2
×′+∂
∂=∂
∂
     (3) 
where 
D  = diffusion coefficient 
'b  = kinetic rate constant 
Wc  = drug concentration into the wall 
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In their paper [2], Idkaek et al. used Cartesian coordinates and not cylindrical 
coordinates. A justification for this approximation can be the relative thinness of the wall 
compared to the overall intestine radius. We used Cartesian coordinates as well. The 
calculation in cylindrical coordinates would have been pretty much the same, and 
regarding our final results this approximation should not have any important impact on 
the concentration values observed in the intestine wall.  
 
 
Figure 9 Small intestine representation. h is the wall thickness, L the small 
intestine length. Axial convection occurs in the x direction, radial diffusion through the 
wall occurs in the y direction. 
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IV - Model development 
 
 
At the intestine lumen inlet, the drug concentration profile coincides with the one 
at the stomach chamber exit. The second boundary condition is the sink assumption in the 
colon. As well as for the stomach, the drug initial profile in the lumen is taken to be zero. 
( ) ( )tctc StL =,0  at 0=x  
 
and   ( ) 00, =xcL    at 0=t      (5) 
 
The mass balance can then be solved analytically using the method of characteristics 
described in appendix B. This leads to the following drug concentration profile: 
( ) ( ) ( ) ( )( ) −××−×−×

 ×−×−×−= x
a
LbTxtkTxtxtTtxcL ˆexpˆˆexp
ˆˆ2expˆˆ4ˆ,ˆˆ ττ  (6) 
 
where 
xˆ  = dimensionless position along the lumen intestine 
 
tˆ  = dimensionless time 
 
The axial position in the intestine is related to the total length of the small intestine L  and 
the time constant
a
LT −= , linking real time to dimensionless time represents the time for 
a particle from the lumen fluid at a velocity a to reach the end of the lumen intestine. 
 
The boundary conditions for the problem of drug diffusion into the wall are on the lumen 
border the concentration in the lumen assorted to a partition coefficient and zero at the 
wall limit for poisoning reasons. Initially there is no drug in the wall. 
( ) ( )
( ) 0,,
ˆ,ˆ,0,
=
×=
thxc
txcPtxc
W
LW  
and ( ) 00,, =yxcW         (7) 
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Appendix C contains the solution procedure of equation (3) for under the above set of 
initial and boundary conditions. The expression derived for the concentration profile in 
the wall is given in terms of the following the Fourier series: 
( ) ( ) ( )txcc
h
yhy
h
ntgtyxc in
n
nW
ˆ,ˆˆsinˆˆ,,ˆ
1
×−+

×= ∑∞
=
π    (8) 
With: 
 
( ) ( ) ( ) ( )( )
( )tTC
tTbt
b
bx
bTb
xK
n
Ptg
nn
nnn
n
ˆexp
ˆexpˆˆ11
ˆ2ˆ
×Γ−×+
×−′×


Γ+−′
−′−+



Γ+−′+×Γ+−′×−= θθ
θθθθ
θ
θπ  
 
And: 
( ) ( ) ( )( )xTbx
b
b
bTb
xK
n
PC n
nnn
n ˆexpˆ11
1ˆ2 ×Γ+−′×












Γ+−′
−′−+



Γ+−′+×Γ+−′×= θθ
θθθ
θ
θπ  
where y  represents the position through the wall.  
 
The origin for y is at the interface between the lumen intestine and the wall, and its upper 
 
 limit is h , the wall thickness.  
 
Note that y is not dimensionless. 
 
Numerically, it can be proven that only a few terms in the Fourier series suffice. The 
series can be truncated pretty fast, since its coefficients are relatively small and 
decreasing with n. The model can in that case be even more simplified. 
The fact that the Fourier coefficients remain small compared to the second part of the 
expression ( )txcc
h
yh
in
ˆ,ˆˆ×−  shows that this linear profile is a good initial guess for the 
concentration profile, since the Fourier series is not correcting it in a considerable way. 
An interpretation of this is that the diffusion is quick enough in comparison with the 
changes in the boundary condition at the wall-lumen interface imposed by convection 
A dynamic distributed-parameter modeling approach for performance monitoring of oral drug delivery systems 36   
 
Pascal Eyriès  Worcester Polytechnic Institute Spring 2003 
phenomenon to reach this linear profile given by the second part of the concentration 
expression. 
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V – Main results and discussion 
 
 
V.1 - Stomach model 
 
The stomach outlet concentration exhibits a zero concentration at the initial time. 
This makes physical sense since at this time none of the drug particles administered had 
enough time to reach the stomach outlet. This would not have been the case though in a 
configuration where the stomach would have been described by one single ideal CSTR. 
Then the concentration reaches a maximum where the largest amount of drug is available 
at the stomach outlet and finally decreases since the majority of the drug has either been 
degraded inside the stomach or has already been driven out in the lumen intestine. The 
two parameters describing this concentration profile are thus the kinetic rate in the 
stomach k and the main residence timeτ . The choice of these parameters is described in 
table 1. Note that τ
J  and the rate constant should be of the same order of magnitude to 
sense their relative influences on the outlet shape. As our main modeling purpose is not 
the stomach but the drug behavior, more importance is given to the rate constant in 
comparison with the ratio τ
J .  
Curve A B C D E 
k  ( )1min −  10-2 10-2 10-2 10-2 10-3 
τ  ( )s  1800 3600 5400 7200 1800 
 
A dynamic distributed-parameter modeling approach for performance monitoring of oral drug delivery systems 38   
 
Pascal Eyriès  Worcester Polytechnic Institute Spring 2003 
 
 
Figure 10 Stomach outlet concentration profiles. 
 
The proposed modeling approach allows the simulation of a broad range of 
dynamic behaviors for the stomach by varying the parameters considered. Moreover, the 
outlet shape can be modified to approach a less distributed concentration profile by 
increasing in the model the number of ideal CSTR in the cascade. Using more than two 
CSTRs in cascade would not complicate the concentration expression in the lumen but 
will drive to more delicate calculations for the diffusion equation in the wall. However, as 
it will be shown further, diffusion through the wall is of much smaller impact on the 
absorbed drug fraction than convection through the lumen. Therefore one could be 
interested in adapting the stomach model to a specific number of reactors and give less 
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importance to the wall diffusion phenomena. For instance a number of CSTRs in cascade 
greater or equal to three will give an initial slope equal to zero, that possibly being one of 
the features one could desire for its lumen time dependant boundary condition. 
In the rest of the simulations, the stomach parameters are set to the ones of curve C, 
which are 210−=k min-1 and 5400=τ sec, that is one hour and a half. This value 
corresponds more or less to an average of digestion time for a human. 
 
 
V.2 – Intestine lumen 
 
The lumen intestine model is depending on the fluid velocity a  and the drug 
disintegration kinetic coefficientb . The fluid velocity is set to its physiological value [2], 
and is thus not a varying parameter in this work. The stomach parameters used are those 
of the set B in table 1. The different values given to the lumen parameters are given in 
table 2 below. 
 
Curve A A’ B C D 
b  (min-1) 5  10-3 10-4 1  10-3 1  10-2 1  10-1 
a  (m/s) 1.1  10-5 1.1  10-5 1.1  10-5 1.1  10-5 1.1 10-5 
 
Figures 11, 12, and 13 are representations of the dimensionless concentration along the 
intestine lumen. The kinetics rate constant was increased from figure 8 to figure 10. On 
these plots the concentration is red on the z axis. These plots show each concentration at 
each time and position along the lumen. The two domains explained in appendix B can be 
observed. For the domain where the dimensionless time tˆ  is less than xˆ  the 
dimensionless position in the intestine, the concentration is zero. This domain matches to 
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all the coordinates where the drug did not had time enough to reach the corresponding 
position. It is delimited by the xt ˆˆ =  line. Above this line is the other domain, where tˆ  is 
greater than xˆ . Here the concentration is different from zero until a certain time. 
Moreover the concentration curve for one fixed xˆ  has the same overall shape than the 
concentration profile at the stomach outlet, moderated by the fact that drug degradation 
occurred within the time the drug took to reach xˆ . 
The influence of the kinetics on the drug distribution along the intestine lumen is of great 
importance. Whereas on figure 11 almost no drug is degraded through the intestine and a 
big amount is going in the colon, on figure 13 the strong kinetics make the drug 
molecules to be degraded far before they reach the end of the small intestine. Thus strong 
degradation kinetics would reduce the surface for the drug to be absorbed in the wall 
along the intestine lumen. 
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Figure 11 Drug concentration profile in the lumen intestine, condition set B. 
 
 
Figure 12 Drug concentration profile in the lumen intestine, condition set C. 
 
 
Figure 13 Drug concentration profile in the lumen intestine, condition set D. 
 
A dynamic distributed-parameter modeling approach for performance monitoring of oral drug delivery systems 42   
 
Pascal Eyriès  Worcester Polytechnic Institute Spring 2003 
 
 
 
Figure 14 represents the mean concentrations along the lumen variation with time. Not 
surprisingly, strong kinetics does not allow the dimensionless concentration to reach very 
high values. From the intermediate concentration profiles C and B to the concentration 
profile A the kinetic rate is decreasing and the effect on the increasing values reached by 
the concentration is understandable. Although the difference between the kinetics rates of 
the concentration profiles A and A’ is of the same order than the one between those of 
profiles A and B, the difference between profiles A and A’ is not of the same magnitude. 
This illustrates the limit of the drug degradation in comparison with the transport 
phenomena. The majority of the drug particles reached by convection the end of the small 
intestine before the drug degradation effect to be of great importance. 
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Figure 14. Mean drug concentration in the lumen versus time. 
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V.3 - Intestine wall 
 
The simulations have been run with the following sets of parameters: 
 
Curve G H I J K L M N 
D (m2/s) 5  10-8 10-8 10-7 10-6 10-3 5  10-8 5  10-8 5  10-8 
'b (min-1) 10-2 10-2 10-2 10-2 10-2 10-3 10-1 1 
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Figure 15 Outer wall concentration profile. Influence of the drug diffusion 
coefficient. 
 
In order to plot the concentration profiles in the wall the values for drug 
degradation rate in the stomach and in the intestine lumen were set up to stationary 
values, so that the only influence on each plot is only the one of the parameter under 
study. 
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Figure 15 represents the influence of the drug diffusivity into the wall. Idkaidek 
and Abdel-Jabbar in [2] used a range of values for D  of the order of 10-4 cm2/s. For these 
values of D , as it can been seen on figure 15, the diffusion coefficient does not have 
much influence on the concentration profile at the absorption point. In a more general 
manner, there are very low differences observed between the concentration profiles with 
even differences between diffusion coefficients of several orders of magnitude. The 
diffusion coefficient does not seem to be a key factor for the transport of the drug through 
the wall. At steady state already, the dimensionless concentration values in the wall 
calculated in [2] were not showing a significant dependence on the diffusion coefficient. 
Moreover the values that were calculated with our model begin at zero, as the drug has 
not reached the wall yet, then increase until an average value of 0.07, and finally decrease 
as the finite amount of drug that was given to the patient was either degraded or removed 
from the small intestine. This value of 0.07 is comparable with the values calculated in 
[2]. 
Figure 16 shows that the drug degradation kinetic rate has some influence when it 
is large enough to affect the drug during its quick diffusion through the wall. The 
concentration profile N represents the concentration profile for a degradation rate of 1 
min-1. This rate is higher of one order of magnitude than the concentration profile M and 
relatively presents a major difference with the other profiles. 
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Figure 16. Outer wall concentration profile. Influence of the drug 
decomposition kinetic rate. 
 
 
V.4 – Small intestine  
 
Interesting information would be to know the ratio of drug molecules initially 
administrated to the patient that are actually absorbed by the body. As our calculations 
have been based on the concentration so far, some more parameters are needed. We 
consider that the human stomach has an average volumeV , the small intestine of length 
L and inner diameter d  with the surrounding wall of thickness h . 
( ) LhdVIntestine ×+×= 2π  
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The drug absorption happens in the external last part of the wall of thickness dy . 
Therefore the volume where no absorption occurs is the volume V ′ of the inner cylinder 
of radius dyhd −+ . 
( ) LdyhdVIntestine ×−+×= 2' π  
Hence the volume where adsorption takes place is, the difference between the two 
previous volumes, that is, assuming dy  small enough to linearize our expression: 
( ) LdyhdVAds ××+×= π2  
Therefore the amount of drug moles adsorbed at the time t  is  
  ( ) ( )∫××= 1
0
0 ˆˆ,,ˆˆ xdtyxccVtn AdsWAds  
Originally the amount of drug moles is 
  00 cVn Stomach ×=  
At the time t  the fraction of drug administrated at first is then 
  ( ) ( )∫= 1
0
ˆˆ,,ˆˆˆ xdtyxc
V
V
tf AdsW
Stomach
Ads  
Upon this drug fraction definition the influence of the different model parameters have 
been studied.  
 
Curve I II III IV V VI VII 
b (min-1) 10-2 10-1 10-4 10-2 10-2 10-1 10-4 
'b (min-1) 10-2 1 10-3 1 10—3 10-2 10-2 
D (m2/s) 5  10-8 5  10-8 10-7 5  10-8 10-7 5  10-8 5  10-8 
 
 Profiles II and III present the two extremes of the fraction of drug profiles. They 
respectively include the parameters that led to low or high concentration values when 
studying independently the lumen intestine and the intestine wall. There is an order 10 of 
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magnitude between the two profiles. A median profile (profile I) was also calculated 
based on the median parameters found in the lumen and the wall. 
Next, in order to study the relative importance on the overall absorption of the 
transport mechanisms in both the lumen and the wall, the parameters of one were fixed at 
median values while these of the other were taking extreme values. Therefore, curve V 
represents the upper extreme of the wall diffusion and curve IV the lower one. On the 
other hand the curve VI is the lower border of the lumen contribution and curve VII its 
higher one. Notice that the lumen transport phenomena are of much greater influence 
than the diffusion through the wall. 
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Figure 17 Cumulative drug concentration available for absorption. 
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VI - Conclusions 
 
The model developed presents a simple analytical solution to a mass balance 
approach to the drug absorption problem in the small intestine. The mass balance 
approach was based on the succession of the transport by convection associated to drug 
degradation in the intestine lumen at first and secondly to diffusion in the intestine wall, 
again associated with drug degradation. The model is then whispered to cover the most 
general case, and as the equations solved are physically based they gave a rigorous and 
comprehensive solution. A time dependant boundary condition for the transport through 
the lumen was imposed by the stomach response to an impulse in the concentration of 
drug. This input for the stomach model corresponds to the sudden swallowing of the drug 
solution by the patient.  
The relative influences of the two transport processes on the drug absorption 
profile were discussed. The transport inside the intestine lumen appears to be of greater 
importance than the diffusion in the wall. 
The concentration profiles and the values obtained match with what can be found 
in the literature. This model is able to provide not only the bioavailability of an oral 
administered drug but also the drug rate absorption.  
Moreover, the model includes a representation for the stomach. This CSTR 
approach of the stomach is not new, but the originality of the approach used is to assume 
a non-ideal CSTR. This allows more flexibility in the concentration profile entering the 
small intestine. The number of reactors in cascade was limited to two, for simplicity 
reasons in the Fourier series development used for the drug diffusion into the wall. As it 
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has been said, wall diffusion shows less influence than lumen convection. Therefore, it 
could be interesting to give more importance to detailing the stomach model with a 
suitable number of CSTRs in cascade, and to assess a linear profile for the drug diffusion 
in the wall. The solution would remain simple in that case. 
The importance of developing an analytical solution resides in the ability this 
provides to go further after the system under consideration with a starting point given by 
the expression found. 
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Appendix A: Concentration derivation at the stomach outlet. 
 
 
• The solution to the differential equation A.1: 
buax
dt
dx +=          (A.1) 
with the initial condition equal to zero and an impulse input 
( )
( ) ( )tMtu
tx
δ=
== 00
 
is found using the Laplace transform.  
In the Laplace domain, equation A.1 becomes, when x is expressed in deviation 
form: 
( ) ( ) bMsaXssX +=         (A.2) 
Where s denotes the Laplace variable 
and the solution of this is then given by 
( )
as
bMsX −=  
Therefore, going back to the time domain 
( ) ( )atbMtx exp=  
Consequently, the expression of x in a non deviation form is: 
( )atbMxx statesteady exp+=  
 
If we consider now the following second differential equation (A.3): 
ax
dt
dx =          (A.3) 
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But with this time the non zero initial condition 
( ) bMtx == 0  
The same method of Laplace transform drives us to the solution 
 ( )atbMxx statesteady exp+=  
which is exactly the same solution than A.1 solution. 
 
• Let’s now consider the case of two CSTRs in cascade, of total volume V. The flux 
going through the two reactors is F. This case is illustrated on figure A.1 next. 
 
Figure A.1 Two identical CSTRs in cascade. 
Writing and solving the mass balances in the two CSTRs in cascade system described 
above is similar to the mathematical approach developed in the first part of this appendix. 
The first CSTR input is an impulse in concentration of magnitude 0c . The mass balance 
on this reactor is thus given by equation A.1: 
  inputckV
Fck
V
F
dt
dc

 
++
 
+−= 22 11       
 (A.1) 
with the set of conditions: 
 
( )
( ) ( )tctc
tc
input δ0
1 00
=
==
 
C1,i 
C1,f 
C2 
V/2 V/2
F F 
F 
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This leads to the solution for ( )tc1 : 
 ( ) ( )( )tkctc τ1exp01 +−×=        (A.3) 
Where 
F
V
2
=τ  
 
The second CSTR is described by the mass balance: 
12
2 22 ck
V
Fck
V
F
dt
dc

 
++
 
+−=       (A.1) 
With the initial condition: 
 ( ) 002 ==tc  
A.1 can be transformed, using the expression previously found for ( )tc1 , in: 
 ( )( )tkk
V
Fck
V
F
dt
dc
τ1exp
22
2
2 +−×
 
++
 
+−=     (A.4) 
According to the solution found for A.2, the solution for A.4 is therefore: 
 ( ) ( )( )tktctc ττ 1exp02 +−×=  
Note that this expression can easily be generalized to the case of J CSTRs in cascade. In 
this case, the solution for the concentration at the outlet of the Jth reactor would be given 
by the expression: 
 ( ) ( ) ( )( )tkn tctc nJJ ττ 1exp!1 110 +−×−= −−  
Where τ  would be in the case of J CSTRs in cascade: 
 
FJ
V=τ  
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Appendix B: Method of characteristics 
 
 
The characteristic method is used to solve the non steady state convection 
equation with a source term due to the first order kinetics of the drug decomposition 
reaction. This equation is written: 
( ) ( ) ( )txcb
x
txca
t
txc
L
LL ,,, ×+∂
∂×=∂
∂       (B1) 
where a stands for the fluid velocity and b for the kinetic rate constant. Notice that both 
a and b are negative values. 
 
(B1) can be rewritten in a dimensionless form: 
( ) ( ) ( )txc
T
Lb
x
txc
L
a
t
txc
T L
LL ˆ,ˆˆ
ˆ
ˆ,ˆˆ
ˆ
ˆ,ˆˆ1 ×=∂
∂×−∂
∂      (B2) 
where L  is the length of the lumen intestine, and 
a
LT −=  a time constant. 
 
In this study the initial concentration profile is taken equal to zero, considering 
that the intestine does not contain any drug: 
( ) ( ) 0ˆ0,ˆ 0 == xcxc LL . 
 
The boundary condition is defined previously as the outlet concentration of a 
semi-batch reactor, thus: 
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( ) ( ) ( )TtkJ
TtJtT
Jtctc
JJ
J
i
LL ××−×−



 ××−××


==
−−
ˆexp
!1
ˆ
exp
ˆˆ)ˆ,0(ˆ
11
τ
ττ . 
 
Equation (B2) is describing a surface ( )txcc LL ˆ,ˆˆˆ =  that can be written in 
parametric forms using two different parameters, s and ζ. (figure B1) 
 
The parameter s describes the surface. It is then possible to write: 
ds
dt
t
c
ds
dx
x
c
ds
cd
∂
∂+∂
∂= ˆˆˆ         (B3) 
 
Identification between the terms of equation (B2) and those of equation (B3) gives the 
following system of ordinary differential equations: 
Tds
td 1ˆ =  
L
a
ds
xd −=ˆ  
( )txc
T
Lb
ds
cd
L
L ˆ,ˆˆ
ˆ ×=  
The integration of this system leads to: 


×=
+−=
+=
s
T
Lbkc
ks
L
ax
ks
T
t
L expˆ
ˆ
1ˆ
3
2
1
 
The next step being to determine the constants 21 , kk  and 3k .  
 
 
• First the initial condition branch is used. This curve is described by: 
A dynamic distributed-parameter modeling approach for performance monitoring of oral drug delivery systems 56   
 
Pascal Eyriès  Worcester Polytechnic Institute Spring 2003 
( )ζ
ζ
0ˆˆ
ˆ
0ˆ
LL cc
x
t
=
=
=
 at s=0 
where ζ is taken between 0 and 1, since it describes xˆ . 
Thus, at s=0: ζ== 21 ,0 kk  and 03 =k . This leads to the expression for the surface 
according to the initial concentration profile: 
ζ+−=
=
s
L
ax
s
T
t
ˆ
1ˆ
 
( ) 0ˆ,ˆˆ =txcL  
As ζ  lies from 0 to 1, this impose the relation between xˆ  and tˆ : 
xt ˆˆ ≤  
 
• Then the boundary condition branch can be used.  
In that case the curve is described by: 
( )ζ
ζ
i
LL cc
x
t
ˆˆ
0ˆ
ˆ
=
=
=
  
Moreover, ζ lies from 0 to infinity.(The time is not bounded as the intestine length is) 
This leads to: 0, 21 == kk ζ  
and ( ) ( ) ( )TkJ
TJT
Jck
JJ
J
i
L ××−×−


 ××−××


==
−−
ζτ
ζζ
ττζ exp!1
exp
ˆ
11
3 . 
Thus, 
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s
L
ax
s
T
t
−=
+=
ˆ
1ˆ ζ
 
Notice that xt ˆˆ −=ζ  and the expression for ( )txcL ˆ,ˆˆ  becomes: 
( ) ( )
( )
( ) ( )( ) −××−×−×−



 ×−×−×−


=
−−
x
a
LbTxtk
J
TxtJxtT
Jtxc
JJ
J
L ˆexpˆˆexp!1
ˆˆ
expˆˆ
ˆ,ˆˆ
11
τ
ττ
 
Moreover, xt ˆˆ −=ζ  impose the validity domain for this expression of ( )txcL ˆ,ˆˆ  to be: 
xt ˆˆ ≥ . 
For the rest of the calculations J is taken equal to 2. 
Thus, the expression for ( )txcL ˆ,ˆˆ  simplifies in 
( ) ( ) ( ) ( )( ) −××−×−×

 ×−×−×−= x
a
LbTxtkTxtxtTtxcL ˆexpˆˆexp
ˆˆ2expˆˆ4ˆ,ˆˆ ττ  
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Figure B1. Concentration surface function of the parameters s andζ . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B2. Validity domains for the expressions of the concentration in the 
intestine lumen. 
 
It is important to note that at the border between the two domains found, the two 
expressions corresponding to each domain match. 
tˆ  
xˆ0 1
1-
( ) ( ) ( )


 −×−×





 −×−−=
T
xtk
T
xtNtxc
ˆˆ
exp
ˆˆ
exp1ˆ,ˆˆ  
( ) 0ˆ,ˆˆ =txc
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Appendix C: Fourier Transform method. 
 
 
The diffusion through the wall is represented by the Fick’s second law associated 
with a source term, due to the drug decomposition kinetics. 
( ) ( ) ( )tycb
y
tyxcD
t
tyxc
T W
WW ˆ,ˆ
ˆ,,ˆˆ
ˆ
ˆ,,ˆˆ1
2
2
′+∂
∂=∂
∂
         (C.1) 
The boundary conditions are: 
( ) ( )
( ) 0ˆ,,ˆˆ
ˆ,ˆˆˆ,0,ˆˆ
=
×=
thxc
txcPtxc
W
LW  
and the initial concentration profile in the wall is zero: 
( ) 00,,ˆˆ =yxcW  
 
The function )ˆ,ˆ(ˆ)ˆ,,ˆ(ˆ)ˆ,,ˆ( txcP
h
yhtyxctyxu LW ×−−= satisfies the equation: 
( ) ( ) ( ) )ˆ,ˆ(ˆˆ,ˆ,,ˆˆ )ˆ,ˆ(ˆ1ˆ ˆ,,ˆ1 2
2
txcP
h
hybtyub
y
tyxuD
t
txcP
h
hy
Tt
tyxu
T L
L ×−′−′+∂
∂=∂
∂×−−∂
∂
            (C.2) 
with the boundary conditions: 
( )
( ) 0ˆ,,ˆ
0ˆ,0,ˆ
=
=
thxu
txu
 
and the initial concentration profile equal to zero as well: 
( ) 00,,ˆ =yxu  
with this new boundary conditions it is possible to define )ˆ,,ˆ( tyxu as a sine Fourier 
Series. 
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∑∞
=


=
1
sin)ˆ()ˆ,,ˆ(
n
n yh
ntgtyxu π  
Recalling ( )txcL ˆ,ˆˆ , the expression for t txcL ˆ )
ˆ,ˆ(ˆ
∂
∂  can be derivated: 
( ) ( ) 

 

 +−×

 −

 +−×=∂
∂ tkTxtkTxK
t
txcL ˆ2expˆˆ21ˆˆ
)ˆ,ˆ(ˆ
ττ  
With: 
( ) 

 

 −+×= x
a
LbkTTTxK ˆ2exp4ˆ ττ  
and the equation C2 can be rearranged as follow: 
)ˆ,,ˆ()ˆ,,ˆ()
ˆ,,ˆ(
ˆ
)ˆ,,ˆ(1
2
2
tyxFtyxub
y
tyxuD
t
tyxu
T
=′−∂
∂−∂
∂     (C.3) 
With:  
( )


 ×′+∂
∂×−= txcb
t
txc
T
P
h
hytyxF LL ˆ,ˆˆˆ
)ˆ,ˆ(ˆ1)ˆ,,ˆ(  for xt ˆˆ ≥ , 
0)ˆ,,ˆ( =tyxF  otherwise. 
 
and )ˆ,,ˆ( tyxF  is developed in a sine Series: 
( ) ∑∞
=


×


 ×′+∂
∂×−=
1
sin2ˆ,ˆˆˆ
)ˆ,ˆ(ˆ1)ˆ,,ˆ(
n
L
L y
h
n
n
txcb
t
txc
T
PtyxF ππ  
Equation C3 can thus reduce to: 
 
( ) ( ) πntxcbt txcTPtgtd tdg LLnnn 2ˆ,ˆˆˆ )
ˆ,ˆ(ˆ1ˆ
ˆ
)ˆ( ×


 ×′+∂
∂×−=×Γ+   (C.4)  
for xt ˆˆ ≥  
 
and:             
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( ) 0ˆˆ )ˆ( =×Γ+ tgtd tdg nnn        (C.4’)  
for xt ˆˆ ≤  
 
where: b
h
nDn ′−

=Γ
2π  
 
The solution of equation C.4’ is trivial due to the zero drug concentration into the 
wall at these moments. 
 
For xt ˆˆ ≥  
By posing: bk ′−+= τθ
2  
The solution of equation C.4 is: 
( ) ( ) ( ) ( )( )
( )tTC
tTbt
b
bx
bTb
xK
n
Ptg
nn
nnn
n
ˆexp
ˆexpˆˆ11
ˆ2ˆ
×Γ−×+
×−′×


Γ+−′
−′−+



Γ+−′+×Γ+−′×−= θθ
θθθθ
θ
θπ  
The integration constant is calculated using the initial zero concentration profile on the 
domain border xt ˆˆ = : 
( ) ( ) ( )( )xTbx
b
b
bTb
xK
n
PC n
nnn
n ˆexpˆ11
1ˆ2 ×Γ+−′×












Γ+−′
−′−+



Γ+−′+×Γ+−′×= θθ
θθθ
θ
θπ
 
Recall that )ˆ,ˆ(ˆ)ˆ,,ˆ()ˆ,,ˆ( txcP
h
yhtyxctyxu W ×−−=  and the concentration of drug into the 
wall is represented by: 
 
( ) ( ) ( )txcc
h
yhy
h
ntgtyxc in
n
nW
ˆ,ˆˆsinˆ,,ˆ
1
×−+

×= ∑∞
=
π  
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Note that, in the formula above, ( )tgn ˆ  is a function vanishing quickly with respect to n.  
In the calculation of the concentration profile the sum has been stopped at n = 4. 
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Notation and abbreviation 
 
 
Nomenclature 
 
a  Fluid velocity in the intestine lumen 
b  Drug decomposition kinetic rate in the intestine lumen 
'b  Drug decomposition kinetic rate in the intestine wall 
c  Concentration 
d  Small intestine diameter (2.5 cm) 
D  Diffusion constant in the wall 
f  Mole fraction absorbed 
h  Wall thickness 
J  Number of ideal CSTR in cascade for the stomach model 
k  Drug decomposition kinetic rate in the stomach 
L Position scale parameter 
V  Stomach volume (1L) 
AdsV  Adsorption region volume 
t  Time 
T Time scale parameter 
τ  Mean residence time of the stomach assimilated to a CSTR 
x  Axial coordinate in the intestine 
y  Position in the intestine wall 
 
Subscripts – superscripts 
 
L  Lumen 
St  Stomach outlet 
W  Intestine wall 
^ Dimensionless expressions 
0 Initial conditions 
 
Abbreviations 
 
Caco Colon Carcinoma Cell 
CAT Compartmental Absorption and Transit 
CSTR Continuously Stirred Tank Reactor 
GI Gastro-Intestinal 
PFR Plug Flow Reactor 
UWL Unstirred Water Layer 
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